Table 2 Possible Risk Factors For CDI in Patients with UC
Univariate Analysis | |||||
|---|---|---|---|---|---|
|  | C. difficile Positive N = 34 | C. difficile Negative N = 68 |  | ||
Factors | N | Positive (%) | N | Negative (%) | P value |
Use of 5-ASA | 29 | 85.3 | 59 | 86.8 | 1.000 |
Use of systemic steroids | 25 | 73.5 | 28 | 41.2 | 0.002 |
Use of immunosuppressants | 5 | 14.7 | 5 | 7.4 | 0.610 |
Use of infliximab | 1 | 2.9 | 2 | 2.9 | 1.000 |
Antibiotic exposure (within 3 mo) | Â | Â | Â | Â | 0.004 |
No | 18 | 62.1 | 52 | 88.1 | Â |
Yes | 11 | 37.9 | 7 | 11.9 | Â |
Missing | 5 | Â | 9 | Â | Â |
Antibiotic exposure (within 1 mo) | Â | Â | Â | Â | 0.936 |
No | 18 | 62.1 | 34 | 63.0 | Â |
Yes | 11 | 37.9 | 20 | 37.0 | Â |
Missing | 5 | Â | 14 | Â | Â |
Use of PPI (within 3 mo) | Â | Â | Â | Â | 0.064 |
No | 20 | 74.1 | 40 | 93.0 | Â |
Yes | 7 | 25.9 | 3 | 7.0 | Â |
Missing | 7 | Â | 25 | Â | Â |
Parenteral nutrition (within 1 mo) | Â | Â | Â | Â | 0.134 |
No | 15 | 60.0 | 42 | 76.4 | Â |
Yes | 10 | 40.0 | 13 | 23.6 | Â |
Missing | 9 | Â | 13 | Â | Â |
Prior hospitalization (within 1 mo) | 23 | 67.6 | 30 | 44.1 | 0.025 |
Active CMV infection | 14 | 42.4 | 10 | 14.7 | 0.001 |
Factors | N | Median (P25, P75) | N | Median (P25, P75) | P value |
Dose of steroids (mg/d) | 34 | 40.0 (0.0, 50.0) | 68 | 0.0 (0.0, 30.0) | 0.001 |
Multivariate Analysis – Logistic Regression | |||||
Factor | Reference | OR (95% CI) | P value | ||
Use of systemic steroids | Yes vs. No | 2.059 (0.155–27.351) | 0.584 | ||
Dose of steroids (mg/d) |  | 0.990 (0.924–1.061) | 0.769 | ||
Antibiotic exposure (within 3 mo) | Yes vs. No | 10.246 (0.867–121.127) | 0.065 | ||
Prior hospitalization (within 1 mo) | Yes vs. No | 2.888 (0.528–15.802) | 0.221 | ||
Active CMV infection | Yes vs. No | 13.502 (1.307–139.512) | 0.029 | ||